Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Leonard Jeff Harris, Kruti Patel, Michael Martin, Leonard Jeff Harris, Kruti Patel, Michael Martin

Abstract

The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC's) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

Keywords: DLBLC; Relapsed or Refractory Diffuse Large B Cell Lymphoma; chemotherapy-free regimen; immunotherapy.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569.
    1. Tkacz J., Garcia J., Gitlin M., McMorrow D., Snyder S., Bonafede M., Chung K.C., Maziarz R.T. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk. Lymphoma. 2020;61:1601–1609. doi: 10.1080/10428194.2020.1734592.
    1. Grimm K.E., O’Malley D.P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann. Diagn. Pathol. 2019;38:6–10. doi: 10.1016/j.anndiagpath.2018.09.014.
    1. Hu S., Xu-Monette Z.Y., Tzankov A., Green T., Wu L., Balasubramanyam A., Liu W.M., Visco C., Li Y., Miranda R.N., et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021–4031. doi: 10.1182/blood-2012-10-460063.
    1. Dunleavy K., Fanale M.A., Abramson J.S., Noy A., Caimi P.F., Pittaluga S., Parekh S., Lacasce A., Hayslip J.W., Jagadeesh D., et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609–e617. doi: 10.1016/S2352-3026(18)30177-7.
    1. Ziepert M., Hasenclever D., Kuhnt E., Glass B., Schmitz N., Pfreundschuh M., Loeffler M. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010;28:2373–2380. doi: 10.1200/JCO.2009.26.2493.
    1. Chapuy B., Stewart C., Dunford A.J., Kim J., Kamburov A., Redd R.A., Lawrence M.S., Roemer M.G.M., Li A.J., Ziepert M., et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 2018;24:679–690. doi: 10.1038/s41591-018-0016-8.
    1. Van Den Neste E., Schmitz N., Mounier N., Gill D., Linch D., Trneny M., Milpied N., Radford J., Ketterer N., Shpilberg O., et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transpl. 2016;51:51–57. doi: 10.1038/bmt.2015.213.
    1. Schuster S.J., Bishop M.R., Tam C.S., Waller E.K., Borchmann P., McGuirk J.P., Jager U., Jaglowski S., Andreadis C., Westin J.R., et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019;380:45–56. doi: 10.1056/NEJMoa1804980.
    1. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D.C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 2010;28:4184–4190. doi: 10.1200/JCO.2010.28.1618.
    1. Crump M. Management of Relapsed Diffuse Large B-cell Lymphoma. Hematol. Oncol. Clin. N. Am. 2016;30:1195–1213. doi: 10.1016/j.hoc.2016.07.004.
    1. Crump M., Kuruvilla J., Couban S., MacDonald D.A., Kukreti V., Kouroukis C.T., Rubinger M., Buckstein R., Imrie K.R., Federico M., et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J. Clin. Oncol. 2014;32:3490–3496. doi: 10.1200/JCO.2013.53.9593.
    1. Ionescu-Ittu R., Shang A., Velde N.V., Guerin A., Lin Y., Shi L., Shi S., Qayum N. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. J. Comp. Eff. Res. 2019;8:1067–1075. doi: 10.2217/cer-2019-0062.
    1. Vosuri V., Kaisreddy R., Bandi S. Comparison of salvage therapies for relapsed or refractory diffuse large B-cell lymphoma (DLBCL): Network meta-analysis. J. Clin. Oncol. 2019;37 doi: 10.1200/JCO.2019.37.15_suppl.e19037.
    1. Nabhan C., Klink A., Lee C.H., Laney J.R., Yang Y., Purdum A.G. Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) J. Clin. Oncol. 2018;36 doi: 10.1200/JCO.2018.36.15_suppl.7545.
    1. Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Westin J., Link B.K., Hay A., Cerhan J.R., Zhu L., et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808. doi: 10.1182/blood-2017-03-769620.
    1. Coyle L., Morley N.J., Rambaldi A., Mason K.D., Verhoef G., Furness C.L., Zhang A., Jung A.S., Cohan D., Franklin J.L. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk. Lymphoma. 2020:1–10. doi: 10.1182/blood-2018-99-112280.
    1. Purdum A., Tieu R., Reddy S.R., Broder M.S. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. Oncologist. 2019;24:1229–1236. doi: 10.1634/theoncologist.2018-0490.
    1. Patel K.K., Isufi I., Kothari S., Foss F., Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leuk. Lymphoma. 2020:1–8. doi: 10.1080/10428194.2020.1808208.
    1. Sehn L.H., Herrera A.F., Flowers C.R., Kamdar M.K., McMillan A., Hertzberg M., Assouline S., Kim T.M., Kim W.S., Ozcan M., et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2020;38:155–165. doi: 10.1200/JCO.19.00172.
    1. Kalakonda N., Maerevoet M., Cavallo F., Follows G., Goy A., Vermaat J.S.P., Casasnovas O., Hamad N., Zijlstra J.M., Bakhshi S., et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511–e522. doi: 10.1016/S2352-3026(20)30120-4.
    1. Salles G., Duell J., Gonzalez Barca E., Tournilhac O., Jurczak W., Liberati A.M., Nagy Z., Obr A., Gaidano G., Andre M., et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978–988. doi: 10.1016/S1470-2045(20)30225-4.
    1. Jurczak W., Zinzani P.L., Hess G., Gaidano G., Provencio M., Nagy Z., Robak T., Maddocks K.J., Buske C., Ambarkhane S., et al. A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma: Long-Term Follow-up, Final Analysis. Blood. 2019;134:4078. doi: 10.1182/blood-2019-124297.
    1. Gribben J.G., Fowler N., Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J. Clin. Oncol. 2015;33:2803–2811. doi: 10.1200/JCO.2014.59.5363.
    1. Nowakowski G.S., Rodgers T.D., Marino D., Frezzato M., Barbui A.M., Castellino C., Meli E., Fowler N.H., Feinberg B.A., Tillmann S., et al. RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8020.
    1. Wang M., Fowler N., Wagner-Bartak N., Feng L., Romaguera J., Neelapu S.S., Hagemeister F., Fanale M., Oki Y., Pro B., et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial. Leukemia. 2013;27:1902–1909. doi: 10.1038/leu.2013.95.
    1. Rose S.C., Catherine C., Lewis D.L. Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide. Cancer Discov. 2020;10:1091. doi: 10.1158/-RW2020-091.
    1. Lu T., Gibiansky L., Li X., Li C., Shi R., Agarwal P., Hirata J., Miles D., Chanu P., Girish S., et al. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk. Lymphoma. 2020:1–10. doi: 10.1080/10428194.2020.1795154.
    1. Shingleton J.R., Dave S.S. Polatuzumab Vedotin Approved for DLBCL. Cancer Discov. 2019;9:OF2. doi: 10.1158/-nb2019-076.
    1. Polavy FDA Prescriber Label. [(accessed on 14 August 2020)]; Available Online: .
    1. Haioun C., Matasar M.J., Sancho J.-M., Viardot A., Hernandez J., Perretti T., McMillan A. POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.TPS8070.
    1. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among Patients in the Medicare Fee-for-Service Program. N. Engl. J. Med. 2009;360:1418–1428. doi: 10.1056/NEJMsa0803563.
    1. Chiappella A., Corradini P. Selective inhibitors of nuclear export in aggressive B-cell lymphomas. Lancet Haematol. 2020;7:e500–e501. doi: 10.1016/S2352-3026(20)30178-2.
    1. Osborne W., Marzolini M., Tholouli E., Ramakrishnan A., Bachier C.R., McSweeney P.A., Irvine D., Zhang M., Al-Hajj M.A., Pule M., et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8001.
    1. Chavez J.C., Bachmeier C., Kharfan-Dabaja M.A. CAR T-cell therapy for B-cell lymphomas: Clinical trial results of available products. Adv. Hematol. 2019;10:2040620719841581. doi: 10.1177/2040620719841581.
    1. Locke F.L., Ghobadi A., Jacobson C.A., Miklos D.B., Lekakis L.J., Oluwole O.O., Lin Y., Braunschweig I., Hill B.T., Timmerman J.M., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42. doi: 10.1016/S1470-2045(18)30864-7.
    1. Fitzgerald L., Kittai A., Nastoupil L.J., Waller A., Jacobson C.A., Saucier A., Kamdar M.K., Spradley J., Denlinger N., Chipman J., et al. Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8039.
    1. Roex G., Feys T., Beguin Y., Kerre T., Poire X., Lewalle P., Vandenberghe P., Bron D., Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 2020;12:194. doi: 10.3390/pharmaceutics12020194.
    1. Abramson J.S., Ghosh N., Smith S.M. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. Am. Soc. Clin. Oncol. Educ. Book. 2020;40:302–313. doi: 10.1200/EDBK_279043.
    1. Neelapu S.S., Locke F.L., Bartlett N.L., Lekakis L.J., Miklos D.B., Jacobson C.A., Braunschweig I., Oluwole O.O., Siddiqi T., Lin Y., et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017;377:2531–2544. doi: 10.1056/NEJMoa1707447.
    1. Hutchings M., Lugtenburg P., Mous R., Clausen M.R., Chamuleau M., Linton K., Rule S., Lopez J.S., Oliveri R.S., DeMarco D., et al. Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8009.
    1. Bannerji R., Allan J.N., Arnason J.E., Brown J.R., Advani R.H., Barnes J.A., Ansell S.M., O’Brien S.M., Chavez J., Duell J., et al. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) Blood. 2019;134:762. doi: 10.1182/blood-2019-122451.
    1. Schuster S.J., Bartlett N.L., Assouline S., Yoon S.-S., Bosch F., Sehn L.H., Cheah C.Y., Shadman M., Gregory G.P., Ku M., et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood. 2019;134:6. doi: 10.1182/blood-2019-123742.
    1. Morschhauser F., Carlo-Stella C., Offner F., Salles G.A., Hutchings M., Iacoboni G., Sureda A., Crump M., Martinez-Lopez J., Thomas D., et al. Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. Blood. 2019;134:1584. doi: 10.1182/blood-2019-123949.
    1. Maddocks K.J., Duell J., Barca E.G., Jurczak W., Liberati A.M., Nagy Z., Obr A., Gaidano G., André M., Kalakonda N., et al. Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis. J. Clin. Oncol. 2019;37 doi: 10.1200/JCO.2019.37.15_suppl.7521.
    1. Advani R.H., Flinn I., Popplewell L., Forero-Torres A., Bartlett N.L., Ghosh N., Kline J.P., Tran T., Lynn J., Chen J.Y., et al. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. J. Clin. Oncol. 2018;36 doi: 10.1200/JCO.2018.36.15_suppl.7504.
    1. Herbaux C., Casasnovas O., Feugier P., Damaj G., Bouabdallah R., Guidez S., Ysebaert L., Tilly H., Gouill S.L., Fornecker L., et al. Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8053.
    1. Chen R.W., Ansell S.M., Zinzani P.L., Vacirca J.L., Lopez-Guillermo A., Hutchings M., Jurczak W., Hess G., Gouill S.L., Offner F., et al. Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) J. Clin. Oncol. 2017;35 doi: 10.1200/JCO.2017.35.15_suppl.TPS7575.
    1. Shah N.N., Zhu F., Schneider D., Taylor C., Krueger W., Worden A., Longo W.L., Hamadani M., Fenske T., Johnson B., et al. Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. J. Clin. Oncol. 2019;37 doi: 10.1200/JCO.2019.37.15_suppl.2510.
    1. Fanale M.A., Hamlin P.A., Park S.I., Persky D.O., Higgins J.P., Burnett C., Dabovic K., Poma E., Sarapa N., Younes A. Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study. J. Clin. Oncol. 2018;36:7580. doi: 10.1200/JCO.2018.36.15_suppl.7580.
    1. Duque A.E.D., Perekhrestenko T., Musteata V., Zodelava M., Guthrie T.H., Strack T., Burnett C., Wilson S., Waltzman R.J., Baetz T.D., et al. A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.TPS8074.
    1. Coleman M., Belada D., Casasnovas R.-O., Gressin R., Lee H.-P., Mehta A., Munoz J., Verhoef G., Corrado C., DeMarini D.J., et al. Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202) J. Clin. Oncol. 2019;37:e19038. doi: 10.1200/JCO.2019.37.15_suppl.e19038.
    1. Coleman M., Forero-Torres A., Ribrag V., Chau I., DeMarini D.J., Zinzani P.L. Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202) J. Clin. Oncol. 2017;35 doi: 10.1200/JCO.2017.35.15_suppl.TPS7579.
    1. Batlevi C.L., Frank S.D., Stewart C., Hamlin P.A., Matasar M.J., Gerecitano J.F., Moskowitz A.J., Hamilton A.M., Zelenetz A.D., Drullinsky P., et al. Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J. Clin. Oncol. 2018;36 doi: 10.1200/JCO.2018.36.15_suppl.7520.
    1. Witzig T.E., Vose J.M., Zinzani P.L., Reeder C.B., Buckstein R., Polikoff J.A., Bouabdallah R., Haioun C., Tilly H., Guo P., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann. Oncol. 2011;22:1622–1627. doi: 10.1093/annonc/mdq626.
    1. Yang H., Xiang B., Song Y., Zhang H., Zhao W., Zou D., Lv F., Bai O., Liu A., Li C., et al. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.e20051.
    1. de la Merino L.C. Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.8019.
    1. Guerra-Bauman F., LaPlant B., Macon W.R., Witzig T.E., Farooq U., Nowakowski G.S., Feldman T. Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network. J. Clin. Oncol. 2020;38 doi: 10.1200/JCO.2020.38.15_suppl.TPS8073.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner